International webinar onCellular and Molecular Biology

Intra-Cellular Therapies acquisition will expand J&J’s presence in neurology space, says GlobalData

Johnson & Johnson (J&J) recently announced the acquisition of Intra-Cellular Therapies, a biopharmaceutical company specialising in the development of treatments targeting complex psychiatric and neurological disorders. The deal is the biggest biotech M&A transaction since 2023. As part of the acquisition, J&J will obtain Intra-Cellular’s extensive neurology portfolio, which will allow them to grow its market share in major indications such as schizophrenia, agitation and psychosis in Alzheimer’s Disease, Parkinson’s disease, and opioid use disorder, says GlobalData.